|Articles|January 27, 2017
Aurinia Selects Worldwide for Phase III Lupus Trial
Aurinia Pharma has announced the selection of Worldwide Clinical Trials as its CRO for the AURORA study.
Advertisement
Aurinia Pharma has announced the selection of Worldwide Clinical Trials as its CRO for the AURORA study, a Phase III clinical trial for the treatment of active lupus nephritis.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
PLPS Launches MyClinicalSuite™ to Deliver Faster Clinical Trial Label Turnarounds Without Compromising Quality, Compliance, or Patient Safety
2
What Clinical Trials Can Learn from the Gig Economy About Payments
3
AI-Driven Clinical Trial Recruitment and Design
4
ACT Brief: RBQM Financial Value Quantified, Sponsor-Configurable AI Systems, and Basket Trials for Rare Pediatrics
5